While the reduction in price target from $7 to $6 by Scotiabank could be seen as a negative signal, the maintenance of a Sector Outperform rating suggests continued confidence in Bionano Genomics' potential. This mixed signal might lead to a neutral short-term impact on BNGO's stock price as investors weigh the lowered price target against the reaffirmed positive outlook.